Impact of guidelines on health care use for the management of dyslipidemia in two Canadian provinces, Alberta and Nova Scotia, from 1990 to 2001

Canadian Journal of Cardiology

Volumn 20, Issue 8, 2004, Pages 767-772

  Joffres, Michael R ^a   Kamath, Tripthi V ^b   Williams, G Rhys ^b   Casey, Jill ^c   Svenson, Lawrence W ^d  

^a DALHOUSIE UNIVERSITY   (Canada)

^b BRISTOL MYERS SQUIBB   (United States)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Guidelines; Hypercholesterolemia; Record linkage

Indexed keywords

ANTILIPEMIC AGENT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; LIPOPROTEIN;

ADULT; AGED; ARTICLE; CANADA; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; DISEASE CLASSIFICATION; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HEALTH EDUCATION; HEALTH SURVEY; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; REGISTER; ADOLESCENT; AGE; BLOOD; CLINICAL PRACTICE; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG UTILIZATION; HEALTH CARE DELIVERY; MEDICAL INFORMATION SYSTEM; MIDDLE AGED; MULTICENTER STUDY; PREVALENCE; SEX DIFFERENCE; STANDARD; STATISTICS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ALBERTA; ANTILIPEMIC AGENTS; CLINICAL PHARMACY INFORMATION SYSTEMS; DELIVERY OF HEALTH CARE; DRUG UTILIZATION; FEMALE; GUIDELINE ADHERENCE; HEALTH SURVEYS; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS; MALE; MIDDLE AGED; NOVA SCOTIA; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PRESCRIPTIONS, DRUG; PREVALENCE; SEX FACTORS; TREATMENT OUTCOME;

EID: 3242746871     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Canadian Consensus Conference on Cholesterol: Final report. The Canadian Consensus Conference on the Prevention of Heart and Vascular Disease by use by Altering Serum Cholesterol and Lipoprotein Risk Factors. CMAJ 1988;139(11 Suppl): 1-8.
2. Wood D, Backer G. Faergeman O. Graham I, Mancia G. Pyorala K. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atheroselerosis 1998;140:199-270.
3. Fodor JG, Frohlich JJ, Genest JJ Jr, McPherson PR. Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemia. CMAJ 2000;162:1441-7.
4. Frohlich J, Fodor G, McPherson R, Genest J, Langner N. Rationale for and outline of the recommendations of the Working Group on Hypercholesterolemia and Other Dyslipidemias: Interim report. Dyslipidemia Working Group of Health Canada. Can J Cardiol 1998;14(Suppl A);17A-21A.
5. The Toronto Working Group on Cholesterol Policy. Asymptomatic hypercholesterolemia: A clinical policy review. J Clin Epidemiol 1990;43:1028-121.
6. Canadian Task Force on the Periodic Health Examination. Periodic health examination, 1993 update: 2. Lowering the blood total cholesterol level to prevent coronary heart disease. CMAJ 1993;148:521-38.
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation. And Treatment of High Blood Cholesterol In Adults (Adult treatment Panel III). JAMA 2001;285:2486-97.
8. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of high Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
9. Feder DO, Koro CE, L'Italien GJ. New National Cholesterol Education Program III guideline for primary prevention lipid-lowering drug therapy: Projected impact on the size, sex, and age distribution of the treatment eligible population. Circulation 2002;105:152-6.
10. National Cholesterol Education Program. The Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Bethesda: National Institutes of Health, 1993.
11. The Expert Panel. Report of the National Cholesterol Education Program Expert Panel Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med 1988;148:36-69.
12. MacLean DR, Petrasovits A, Connelly PW, Little JA, O'Connor B. for the Canadian Heart Health Surveys Research Group. Impact of different blood lipid evaluation and treatment guidelines on the proportion of Canadian identified and treatment for elevated blood cholesterol. Can J Cardiol 1999;15;445-51.
13. Joffres MR, Titanich KL, Hesel PA. The Alberta Heart Healt Survey: Methods and results. Can Cardiol 1993;9:300-8.
14. Jofffres M, MacLean DR. O'Connor BA. Petrasovit A, Stachenko S, eds. Canadians Heart Health. Cat no. H39-328/1995E. Ottawa: Health Canada, Minister of Supply and Services Canada, 1995.
15. Population Health Research Unit. (Version current at April 19, 2004).
16. International Classification Diseases, 9th revision (Clinical Modification). Washington: Public Health Service, US Department of Health and Human Services, 1988.
17. Province of Nova Scotia and Heart Health Nova Scotia. The Nova Scotia Health Survey, 1995. Halifax: Communication, Nova Scotia, 1996.
18. Kephart G. Skeris I, MacLean D, Kass K, Nagpal S. Management of high blood cholesterol level in Nova Scotia adults: Comparison with the NCEP II and European clinical practice guidelines. Am J Manag Care 2000;6:1017-28.
19. Sketris IS, Kephart GC, Hicks VA, et al. Prescribing patterns of antilipemic drugs and prevalence of hypercholesterolemia in the nova Scotia population more than 65 years old, Ann Pharmacother 1995;29:576-81.
20. MacLean DR, Farquharson J, Heath S, Barkhouse K, Latter C, Joffres C. Building capacity for heart health promotion: Result of a 5-year experience in Nova Scotia, Canada. Am J Health Promot 2003;17:202-12.
21. Cox JL. Optimizing disease management at healt care system level: The rational and methods of the improving cardiovascular outscomes in Nova Scotia (ICONS) Study. Can J. Cardiol 1999; 15:787-96.
22. Grover SA, Dorias M. Paradis G. et al. Lipid screening to prevent coronary artery disease: A quantitative evaluation of evolving guidelines CMAJ 2000;163:1263-9.
23. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study, Group Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1301-7.
24. Shepherd J, Blauw GJ, Murphy MB, et al, on behalf of the PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002;360:1623-30.
25. Heart Protection Study Collaborate Group. MRC/BHF heart Protection Study cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:7-22.
26. Waters DD. What do the statin trials tell us? Am J Manag Care 2001;7(5 Supp1):S138-43.